Key result
The ivabradine-flecainide combination was effective in completely suppressing congenital junctional ectopic tachycardia resistant to other antiarrhythmic agents.
Why the study?
Congenital junctional ectopic tachycardia is a rare tachyarrhythmia that remains difficult to manage, with suboptimal control in most cases.
Does the ivabradine-flecainide combination improve arrhythmia control in pediatric patients with congenital junctional ectopic tachycardia resistant to conventional therapy?
Case Report
Does the ivabradine-flecainide combination improve arrhythmia control in pediatric patients with congenital junctional ectopic tachycardia resistant to conventional therapy?
The combination of ivabradine and flecainide may serve as a breakthrough therapy for congenital junctional ectopic tachycardia resistant to conventional antiarrhythmic agents.
No takes yet. Share an insight, caveat, or question.
May control refractory pediatric CJET; hypothesis-generating and requires prospective validation.
Marco et al. (2021) conducted a case report in Congenital junctional ectopic tachycardia (CJET). Ivabradine-flecainide combination was evaluated on Suppression of junctional ectopic tachycardia. The ivabradine-flecainide combination was effective in completely suppressing congenital junctional ectopic tachycardia resistant to other antiarrhythmic agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: